How do peptides like AOD-9604 and MOTS-c specifically target stored fat differently than appetite suppressants?

AOD-9604 directly promotes lipolysis and inhibits lipogenesis, specifically targeting fat cells for breakdown without impacting appetite or blood glucose levels. In contrast, MOTS-c enhances metabolic flexibility and insulin sensitivity, encouraging the body to burn fat for energy and improving glucose utilization, which indirectly supports fat loss without affecting hunger signals. These mechanisms focus on metabolic pathways rather than neurochemical appetite control.

What makes Tesamorelin uniquely effective for reducing visceral fat compared to other fat-loss peptides?

Tesamorelin, a Growth Hormone-Releasing Hormone (GHRH) analog, specifically stimulates the pituitary gland to increase endogenous growth hormone production. This sustained increase in GH has been clinically shown to significantly reduce visceral adipose tissue (VAT), particularly in cases like HIV-associated lipodystrophy, a distinct mechanism from peptides that directly act on fat cells or metabolic pathways. Studies, including a 2011 *New England Journal of Medicine* publication, highlight its targeted effect on VAT.

Are there specific dosing considerations for 5-amino-1MQ to maximize its stored fat-burning effects while ensuring safety?

While 5-amino-1MQ research is ongoing, studies typically suggest doses ranging from 20-50 mg daily, often administered orally, to inhibit NAMPT and impact adipose tissue metabolism. It's crucial to follow specific research protocols, as the optimal therapeutic window for human fat loss is still being defined, and interactions with NAD+ levels require careful consideration to avoid potential metabolic imbalances. Always consult a healthcare professional for personalized guidance based on your individual health profile.

Can AOD-9604 truly target localized fat deposits, such as stubborn belly fat, or is its effect more systemic?

AOD-9604's mechanism, derived from the C-terminal fragment of human growth hormone, specifically targets adipose tissue to stimulate lipolysis and inhibit lipogenesis without affecting glucose metabolism or growth. While initial research suggested potential for localized fat reduction, particularly through subcutaneous injection, studies confirm its systemic effect on fat metabolism. However, its direct action on fat cells makes it a strong candidate for overall fat reduction, with some anecdotal reports supporting its efficacy in stubborn areas.

How does MOTS-c's approach to fat burning compare to AOD-9604, especially regarding metabolic health benefits beyond just fat reduction?

MOTS-c primarily functions by improving metabolic flexibility, enhancing insulin sensitivity, and promoting the browning of white adipose tissue, leading to increased energy expenditure and overall metabolic health benefits. AOD-9604, conversely, acts directly on fat cells to stimulate fat breakdown and prevent new fat formation. While both aid in fat loss, MOTS-c offers broader systemic metabolic improvements, whereas AOD-9604 provides a more direct, targeted approach to adipose tissue reduction.

PeptideKey Health Goals

Burn Stored Fat: Peptides That Actually Work [2026]

AOD-9604, MOTS-c, Tesamorelin, and 5-amino-1MQ for fat loss. Which target stored fat vs. appetite? Mechanisms and study results compared.

This goal guide is part of PeptideKey's evidence-based peptide research library covering 100+ compounds with lab-verified purity data.